drugset / Trial / NCT03638141
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Phase 2
Completed
21 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.
Timeline
- Start
- 2019-10-02
- Primary completion
- 2024-08-20
- Completion
- 2024-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 300 mg | Intravenous |